Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery
Journal of Peptide Science · 2025-10 · 31 (10)
DOI: 10.1002/psc.70054 ↗At a glance
Journal article in Journal of Peptide Science, published online on 2025-09-07. Written by Tõnis Lehto and 7 co-authors. Institution: Institute of Technology, University of Tartu, Tartu, Estonia. Major MEDLINE topics: Alanine, RNA, Small Interfering, Peptides, Nanoparticle Drug Delivery System. Cited 4 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: Horizon 2020 Framework Programme, Swedish Foundation of Strategic Research FormulaEx, HORIZON EUROPE European Research Council.
Abstract (original language)
The development of therapeutic small interfering RNAs (siRNAs) has lately gained significant momentum due to their ability to silence genes in a highly specific manner. The main obstacle withholding the wider translation of siRNA‐based drug modalities is their limited half‐life and poor bioavailability, especially in extra‐hepatic tissues. Consequently, various drug delivery systems (DDSs) have been developed to improve the delivery of siRNAs, including short delivery peptides called cell‐penetrating peptides (CPPs). In this study, we explore the potential of using alkenyl‐alanine modifications to enhance the siRNA delivery efficacy with CPPs. We demonstrate on hPep peptides that incorporation of alkenyl‐alanines enhances the encapsulation of siRNAs into stable nanoparticles and contributes to increased cellular uptake. Furthermore, we demonstrate that the lead peptide, hPep3, induces effective RNAi‐mediated gene silencing in a reporter cell model as well as on the disease‐implicated endogenous CD45 gene target. The biodistribution studies in mice show that the alkenyl‐alanines are systemically well tolerated, and employing such modifications in the peptide backbone improves siRNA delivery in several tissues, including extra‐hepatic sites. As demonstrated on hPep peptides, alkenyl‐alanines offer a simple yet robust way to enhance the delivery efficacy of CPPs and have the potential to advance siRNA therapeutics beyond the liver targets.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Technology, University of Tartu, Tartu, Estonia.
- Faculty of Medicine, Institute of Pharmacy, University of Tartu, Tartu, Estonia.
- Division for Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
- Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
- Center of Research and Strategic Studies, Lebanese French University, Erbil, Iraq.
ORCID profiles: Tõnis Lehto, Helena Sork, Annely Lorents, Oscar P B Wiklander, Taavi Lehto
Funding
- Horizon 2020 Framework Programme
- Swedish Foundation of Strategic Research FormulaEx
- HORIZON EUROPE European Research Council
- Cancerfonden
- Swedish Research Council
- Estonian Research Council
- Vetenskapsrådet
- Eesti Teadusagentuur
Cite
APA
Lehto, T., Isakannu, M., Sork, H., Lorents, A., Bazaz, S., Wiklander, O. P. B., Andaloussi, S. E., & Lehto, T. (2025). Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery. Journal of Peptide Science, 31(10). https://doi.org/10.1002/psc.70054
Vancouver
Lehto T, Isakannu M, Sork H, Lorents A, Bazaz S, Wiklander OPB, et al. Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery. Journal of Peptide Science. 2025;31(10). doi:10.1002/psc.70054
BibTeX
@article{Lehto2025,
author = {Lehto, Tõnis and Isakannu, Marit and Sork, Helena and Lorents, Annely and Bazaz, Safa and Wiklander, Oscar P B and Andaloussi, Samir El and Lehto, Taavi},
title = {Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery},
journal = {Journal of Peptide Science},
year = {2025},
volume = {31},
number = {10},
doi = {10.1002/psc.70054}
}
EUVIMED